Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 307 EUR -1.6% Market Closed
Market Cap: 2.6B EUR

EV/EBIT
Enterprise Value to EBIT

12.2
Current
12.7
Median
16
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
12.2
=
Enterprise Value
2.7B EUR
/
EBIT
218.6m EUR
Market Cap EV/EBIT
FR
Virbac SA
PAR:VIRP
2.6B EUR 12.2
US
Eli Lilly and Co
NYSE:LLY
676.4B USD 35.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
367.9B USD 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 14.6
CH
Roche Holding AG
SIX:ROG
206.7B CHF 11
CH
Novartis AG
SIX:NOVN
181.7B CHF 13.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 197.2
US
Merck & Co Inc
NYSE:MRK
195.2B USD 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 655.3
US
Pfizer Inc
NYSE:PFE
132.6B USD 10.2
EBIT Growth EV/EBIT to Growth
FR
Virbac SA
PAR:VIRP
Average EV/EBIT: 1 698.1
12.2
7%
1.7
US
Eli Lilly and Co
NYSE:LLY
35.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
11.7
2-Years Forward
EV/EBIT
10.8
3-Years Forward
EV/EBIT
9.8